Physician profile
Robert A Graor
NPI 1114926409
$10,734.96
in general payments reported to CMS, 2019-2025
29 companies · $3,261 in 2025
The $3,261 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,523 · 2020: $2,113 · 2021: $866 · 2022: $328 · 2023: $1,245 · 2024: $1,399 · 2025: $3,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140 · Travel and Lodging: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,139.52 |
| Travel and Lodging | $1,765.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,928.08 | 2019-2025 | Aveir, Gallant, Merlin@Home |
| Abiomed | $3,383.06 | 2019-2025 | Impella |
| Medtronic Vascular, INC. | $1,599.66 | 2020 | |
| Boston Scientific Corporation | $190.52 | 2020-2025 | Avvigo Guidance System |
| Amgen INC. | $181.87 | 2019-2024 | Repatha |
| Shockwave Medical, INC | $178.42 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $120.47 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $114.10 | 2019 | |
| Edwards Lifesciences Corporation | $109.57 | 2019 | |
| Cardiovascular Systems INC. | $103.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $97.40 | 2023-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $89.46 | 2019-2021 | |
| Medtronic, INC. | $79.12 | 2022-2024 | Onyx Frontier |
| Medline Industries LP | $75.91 | 2025 | |
| Chiesi USA, INC. | $68.22 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $62.70 | 2022-2023 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.00 | 2019-2025 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $37.94 | 2023 | Arcalyst |
| Inari Medical, INC. | $37.14 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kiniksa Pharmaceuticals International, Plc | $36.28 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.75 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $31.80 | 2019 | |
| Davol INC. | $26.56 | 2021 | |
| Alnylam Pharmaceuticals INC. | $23.17 | 2024 | Amvuttra |
| Biosense Webster, INC. | $20.23 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $19.60 | 2024 | |
| Scpharmaceuticals INC. | $15.05 | 2025 | |
| Pfizer INC. | $13.90 | 2025 | |
| Philips North America LLC | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Graor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.